| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S2409-ESCLC, Durvalumab +/- Biomarker Directed Tx | 1 | Y | 0 Screening & Cohort Assignment | 900 | 63 | 63 | 44 | 24 | 10 | 0 | 11/06/2025 | 234 | 73 |
| 63 | 63 | 44 | 24 | 10 | 0 | |||||||||
| 2 | Y | 1 Durvalumab | 9 | 9 | 8 | 5 | 1 | 1 | 11/06/2025 | |||||
| 2 Durvalumab + Saruparib | 5 | 5 | 4 | 2 | 1 | 0 | ||||||||
| 5 Durvalumab | 1 | 1 | 1 | 0 | 0 | 0 | ||||||||
| 6 Durvalumab + Monalizumab | 1 | 1 | 1 | 1 | 0 | 0 | ||||||||
| 16 | 16 | 14 | 8 | 2 | 1 | |||||||||
| S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | 1 | Y | 1 Durvalumab | 306 | 7 | 5 | 4 | 2 | 0 | 0 | 04/01/2025 | 270 | 87 | |
| 2 Surveillance | 7 | 6 | 3 | 3 | 1 | 0 | ||||||||
| 14 | 11 | 7 | 5 | 1 | 0 | |||||||||
| Yes | A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 1 | E | Total Registrations | 109 | 11 | 6 | 1 | 0 | 0 | 10/20/2020 | 441 | 173 | |
| 109 | 11 | 6 | 1 | 0 | 0 | |||||||||
| EA5162-NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 | 1 | E | Total Registrations | 4 | 0 | 0 | 0 | 0 | 0 | 08/23/2023 | 88 | 33 | ||
| 4 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 1 | E | Total Registrations | 26 | 1 | 0 | 0 | 0 | 0 | 04/28/2021 | 227 | 81 | ||
| 26 | 1 | 0 | 0 | 0 | 0 | |||||||||
| EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno | 1 | E | Total Registrations | 7 | 4 | 2 | 2 | 1 | 0 | 08/07/2024 | 217 | 82 | ||
| 7 | 4 | 2 | 2 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 6 | 4 | 2 | 2 | 1 | 0 | 08/07/2024 | |||||
| 6 | 4 | 2 | 2 | 1 | 0 | |||||||||
| NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | 1 | E | Total Registrations | 5 | 2 | 0 | 0 | 0 | 0 | 01/26/2024 | 350 | 136 | ||
| 5 | 2 | 0 | 0 | 0 | 0 | |||||||||